US research institution started new clinical trial of Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center is starting a new clinical trial of Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders.
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
The clinical trial started on November 20, 2020 and will continue throughout December 20, 2022.
Patients with age ≤ 21 years at the time of consent with no available and suitably matched related or unrelated donor in the required time period can be enrolled in this study.
Patients with the following disorders and condition: Acute myelogenous leukemia (AML), Acute lymphoblastic leukemia, Other acute leukemias, Myelodysplastic Syndrome (MDS) / Myeloproliferative Disorders (MPD) other than myelofibrosis, Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission, Inherited Metabolic Disorders and Non-Malignant disorders can be included for participation.
Among the exclusion criteria are:
- Inadequate performance status/ organ function.
- Advanced metabolic disease (EBMT handbook).
- Active CNS leukemic involvement.
- Indolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage chemotherapy.
- Diagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow fibrosis.
and others
The contacts and locations are the Memorial Sloan Kettering Cancer Center, New York, United States.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04644016
